Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Identifieur interne : 008563 ( Main/Exploration ); précédent : 008562; suivant : 008564Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Auteurs : Giuseppe Viale [Royaume-Uni] ; Anita Giobbie-Hurder [Royaume-Uni] ; Meredith M. Regan [Royaume-Uni] ; Alan S. Coates [Royaume-Uni] ; Mauro G. Mastropasqua [Royaume-Uni] ; Patrizia Dell'Orto [Royaume-Uni] ; Eugenio Maiorano [Royaume-Uni] ; Gaëtan Macgrogan [Royaume-Uni] ; Stephen G. Braye [Royaume-Uni] ; Christian Öhlschlegel [Royaume-Uni] ; Patrick Neven [Royaume-Uni] ; Zsolt Orosz [Royaume-Uni] ; Wojciech P. Olszewski [Royaume-Uni] ; Fiona Knox [Royaume-Uni] ; Beat Thürlimann [Royaume-Uni] ; Karen N. Price [Royaume-Uni] ; Monica Castiglione-Gertsch [Royaume-Uni] ; Richard D. Gelber [Royaume-Uni] ; Barry A. Gusterson [Royaume-Uni] ; Aron Goldhirsch [Royaume-Uni]Source :
- Journal of Clinical Oncology [ 0732-183X ] ; 2008.
Abstract
To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer.
Breast International Group (BIG) trial 1-98 randomly assigned 8,010 patients to four treatment arms comparing Let and Tam with sequences of each agent. Of 4,922 patients randomly assigned to receive 5 years of monotherapy with either agent, 2,685 had primary tumor material available for central pathology assessment of Ki-67 LI by immunohistochemistry and had tumors confirmed to express estrogen receptors after central review. The prognostic and predictive value of centrally measured Ki-67 LI on disease-free survival (DFS) were assessed among these patients using proportional hazards modeling, with Ki-67 LI values dichotomized at the median value of 11%.
Higher values of Ki-67 LI were associated with adverse prognostic factors and with worse DFS (hazard ratio [HR; high:low] = 1.8; 95% CI, 1.4 to 2.3). The magnitude of the treatment benefit for Let versus Tam was greater among patients with high tumor Ki-67 LI (HR [Let:Tam] = 0.53; 95% CI, 0.39 to 0.72) than among patients with low tumor Ki-67 LI (HR [Let:Tam] = 0.81; 95% CI, 0.57 to 1.15; interaction
Ki-67 LI is confirmed as a prognostic factor in this study. High Ki-67 LI levels may identify a patient group that particularly benefits from initial Let adjuvant therapy.
Url:
DOI: 10.1200/JCO.2008.17.0829
PubMed: 18981464
PubMed Central: 2651094
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001019
- to stream Pmc, to step Curation: 000E80
- to stream Pmc, to step Checkpoint: 002936
- to stream Ncbi, to step Merge: 000476
- to stream Ncbi, to step Curation: 000476
- to stream Ncbi, to step Checkpoint: 000476
- to stream Main, to step Merge: 008D92
- to stream Main, to step Curation: 008563
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole</title><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Giobbie Hurder, Anita" sort="Giobbie Hurder, Anita" uniqKey="Giobbie Hurder A" first="Anita" last="Giobbie-Hurder">Anita Giobbie-Hurder</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Mastropasqua, Mauro G" sort="Mastropasqua, Mauro G" uniqKey="Mastropasqua M" first="Mauro G." last="Mastropasqua">Mauro G. Mastropasqua</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Dell Orto, Patrizia" sort="Dell Orto, Patrizia" uniqKey="Dell Orto P" first="Patrizia" last="Dell'Orto">Patrizia Dell'Orto</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Maiorano, Eugenio" sort="Maiorano, Eugenio" uniqKey="Maiorano E" first="Eugenio" last="Maiorano">Eugenio Maiorano</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Macgrogan, Gaetan" sort="Macgrogan, Gaetan" uniqKey="Macgrogan G" first="Gaëtan" last="Macgrogan">Gaëtan Macgrogan</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Braye, Stephen G" sort="Braye, Stephen G" uniqKey="Braye S" first="Stephen G." last="Braye">Stephen G. Braye</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Ohlschlegel, Christian" sort="Ohlschlegel, Christian" uniqKey="Ohlschlegel C" first="Christian" last="Öhlschlegel">Christian Öhlschlegel</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Orosz, Zsolt" sort="Orosz, Zsolt" uniqKey="Orosz Z" first="Zsolt" last="Orosz">Zsolt Orosz</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Olszewski, Wojciech P" sort="Olszewski, Wojciech P" uniqKey="Olszewski W" first="Wojciech P." last="Olszewski">Wojciech P. Olszewski</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Knox, Fiona" sort="Knox, Fiona" uniqKey="Knox F" first="Fiona" last="Knox">Fiona Knox</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Castiglione Gertsch, Monica" sort="Castiglione Gertsch, Monica" uniqKey="Castiglione Gertsch M" first="Monica" last="Castiglione-Gertsch">Monica Castiglione-Gertsch</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Gusterson, Barry A" sort="Gusterson, Barry A" uniqKey="Gusterson B" first="Barry A." last="Gusterson">Barry A. Gusterson</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18981464</idno><idno type="pmc">2651094</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651094</idno><idno type="RBID">PMC:2651094</idno><idno type="doi">10.1200/JCO.2008.17.0829</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">001019</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001019</idno><idno type="wicri:Area/Pmc/Curation">000E80</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E80</idno><idno type="wicri:Area/Pmc/Checkpoint">002936</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002936</idno><idno type="wicri:Area/Ncbi/Merge">000476</idno><idno type="wicri:Area/Ncbi/Curation">000476</idno><idno type="wicri:Area/Ncbi/Checkpoint">000476</idno><idno type="wicri:doubleKey">0732-183X:2008:Viale G:prognostic:and:predictive</idno><idno type="wicri:Area/Main/Merge">008D92</idno><idno type="wicri:Area/Main/Curation">008563</idno><idno type="wicri:Area/Main/Exploration">008563</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole</title><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Giobbie Hurder, Anita" sort="Giobbie Hurder, Anita" uniqKey="Giobbie Hurder A" first="Anita" last="Giobbie-Hurder">Anita Giobbie-Hurder</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Mastropasqua, Mauro G" sort="Mastropasqua, Mauro G" uniqKey="Mastropasqua M" first="Mauro G." last="Mastropasqua">Mauro G. Mastropasqua</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Dell Orto, Patrizia" sort="Dell Orto, Patrizia" uniqKey="Dell Orto P" first="Patrizia" last="Dell'Orto">Patrizia Dell'Orto</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Maiorano, Eugenio" sort="Maiorano, Eugenio" uniqKey="Maiorano E" first="Eugenio" last="Maiorano">Eugenio Maiorano</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Macgrogan, Gaetan" sort="Macgrogan, Gaetan" uniqKey="Macgrogan G" first="Gaëtan" last="Macgrogan">Gaëtan Macgrogan</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Braye, Stephen G" sort="Braye, Stephen G" uniqKey="Braye S" first="Stephen G." last="Braye">Stephen G. Braye</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Ohlschlegel, Christian" sort="Ohlschlegel, Christian" uniqKey="Ohlschlegel C" first="Christian" last="Öhlschlegel">Christian Öhlschlegel</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Orosz, Zsolt" sort="Orosz, Zsolt" uniqKey="Orosz Z" first="Zsolt" last="Orosz">Zsolt Orosz</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Olszewski, Wojciech P" sort="Olszewski, Wojciech P" uniqKey="Olszewski W" first="Wojciech P." last="Olszewski">Wojciech P. Olszewski</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Knox, Fiona" sort="Knox, Fiona" uniqKey="Knox F" first="Fiona" last="Knox">Fiona Knox</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Castiglione Gertsch, Monica" sort="Castiglione Gertsch, Monica" uniqKey="Castiglione Gertsch M" first="Monica" last="Castiglione-Gertsch">Monica Castiglione-Gertsch</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Gusterson, Barry A" sort="Gusterson, Barry A" uniqKey="Gusterson B" first="Barry A." last="Gusterson">Barry A. Gusterson</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation wicri:level="1"><nlm:aff id="aff0">From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>From the Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan; Department of Pathological Anatomy, University of Bari, Bari, Italy; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center; Swiss Group for Clinical Cancer Research (SAKK), Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle and Anatomical Pathology, Hunter Area Pathology Service, John Hunter Hospital, New South Wales, Australia; Department of Pathology, Institut Bergonié, Bordeaux, France; Department of Gynecologic Oncology and Multidisciplinary Breast Centre, UZ-KU Leuven, Leuven, Belgium; Department of Pathology, National Institute of Oncology, Budapest, Hungary; Center of Oncology-Institute, Warsaw, Poland; Department of Pathology, South Manchester University Hospital, Manchester; and the Division of Cancer Sciences and Molecular Pathology, Glasgow University</wicri:regionArea><wicri:noRegion>Glasgow University</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer.</p></sec><sec><title>Patients and Methods</title><p>Breast International Group (BIG) trial 1-98 randomly assigned 8,010 patients to four treatment arms comparing Let and Tam with sequences of each agent. Of 4,922 patients randomly assigned to receive 5 years of monotherapy with either agent, 2,685 had primary tumor material available for central pathology assessment of Ki-67 LI by immunohistochemistry and had tumors confirmed to express estrogen receptors after central review. The prognostic and predictive value of centrally measured Ki-67 LI on disease-free survival (DFS) were assessed among these patients using proportional hazards modeling, with Ki-67 LI values dichotomized at the median value of 11%.</p></sec><sec><title>Results</title><p>Higher values of Ki-67 LI were associated with adverse prognostic factors and with worse DFS (hazard ratio [HR; high:low] = 1.8; 95% CI, 1.4 to 2.3). The magnitude of the treatment benefit for Let versus Tam was greater among patients with high tumor Ki-67 LI (HR [Let:Tam] = 0.53; 95% CI, 0.39 to 0.72) than among patients with low tumor Ki-67 LI (HR [Let:Tam] = 0.81; 95% CI, 0.57 to 1.15; interaction <italic>P</italic> = .09).</p></sec><sec><title>Conclusion</title><p>Ki-67 LI is confirmed as a prognostic factor in this study. High Ki-67 LI levels may identify a patient group that particularly benefits from initial Let adjuvant therapy.</p></sec></div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name></noRegion><name sortKey="Braye, Stephen G" sort="Braye, Stephen G" uniqKey="Braye S" first="Stephen G." last="Braye">Stephen G. Braye</name><name sortKey="Castiglione Gertsch, Monica" sort="Castiglione Gertsch, Monica" uniqKey="Castiglione Gertsch M" first="Monica" last="Castiglione-Gertsch">Monica Castiglione-Gertsch</name><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><name sortKey="Dell Orto, Patrizia" sort="Dell Orto, Patrizia" uniqKey="Dell Orto P" first="Patrizia" last="Dell'Orto">Patrizia Dell'Orto</name><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><name sortKey="Giobbie Hurder, Anita" sort="Giobbie Hurder, Anita" uniqKey="Giobbie Hurder A" first="Anita" last="Giobbie-Hurder">Anita Giobbie-Hurder</name><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><name sortKey="Gusterson, Barry A" sort="Gusterson, Barry A" uniqKey="Gusterson B" first="Barry A." last="Gusterson">Barry A. Gusterson</name><name sortKey="Knox, Fiona" sort="Knox, Fiona" uniqKey="Knox F" first="Fiona" last="Knox">Fiona Knox</name><name sortKey="Macgrogan, Gaetan" sort="Macgrogan, Gaetan" uniqKey="Macgrogan G" first="Gaëtan" last="Macgrogan">Gaëtan Macgrogan</name><name sortKey="Maiorano, Eugenio" sort="Maiorano, Eugenio" uniqKey="Maiorano E" first="Eugenio" last="Maiorano">Eugenio Maiorano</name><name sortKey="Mastropasqua, Mauro G" sort="Mastropasqua, Mauro G" uniqKey="Mastropasqua M" first="Mauro G." last="Mastropasqua">Mauro G. Mastropasqua</name><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name><name sortKey="Ohlschlegel, Christian" sort="Ohlschlegel, Christian" uniqKey="Ohlschlegel C" first="Christian" last="Öhlschlegel">Christian Öhlschlegel</name><name sortKey="Olszewski, Wojciech P" sort="Olszewski, Wojciech P" uniqKey="Olszewski W" first="Wojciech P." last="Olszewski">Wojciech P. Olszewski</name><name sortKey="Orosz, Zsolt" sort="Orosz, Zsolt" uniqKey="Orosz Z" first="Zsolt" last="Orosz">Zsolt Orosz</name><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008563 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008563 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:2651094
|texte= Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18981464" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |